灯盏花素联合神经生长因子治疗缺血性视神经病变的效果

Effect of breviscapine combined with nerve growth factor on patients with ischemic optic neuropathy

目的分析灯盏花素联合神经生长因子治疗缺血性视神经病变的临床效果。方法选取2015年1月至2019年1月林州市中医院122例缺血性视神经病变患者为研究对象,按照随机数表法分为对照组与观察组,每组61例。对照组在常规治疗基础上采用神经生长因子,观察组在对照组治疗基础上联合灯盏花素治疗,均治疗4周。比较两组患者治疗效果、治疗后视力水平、视野缺损情况及不良反应。结果治疗后,观察组治疗总有效率[98.36%(60/61)]、视力[(0.55±0.13)D]、视野平均光敏感度(20.10±3.82)均高于对照组[86.89%(53/61)、(0.41±0.11)D、(17.23±3.87)],差异有统计学意义(P<0.05)。观察组视野丢失差异(14.85±2.81)、视野平均损害[(5.19±1.41)dB]均低于对照组[(20.02±2.97)、(8.05±1.89)dB],差异有统计学意义(P<0.05)。观察组不良反应发生率略高于对照组,差异未见统计学意义(P>0.05)。结论将灯盏花素与神经生长因子联合用于缺血性视神经病变患者的治疗中,能显著增强患者视力水平,改善视野缺损情况,提高临床治疗效果,虽一定程度上增加了不良反应发生率,但在患者耐受范围内。

Objective To analyze the effect of Breviscapine combined with nerve growth factor on patients with ischemic optic neuropathy.Methods A total of 122 patients with ischemic optic neuropathy in Linzhou Hospital of Traditional Chinese Medicine from January 2015 to January 2019 were selected as the study subjects. They were divided into control group and observation group according to random number table method, with 61 cases in each group. The control group was treated with nerve growth factor on the basis of routine treatment, while the observation group was treated with Breviscapine on the basis of the control group for 4 weeks. The therapeutic effect, visual acuity, visual field defect and adverse reactions were compared between the two groups.Results After treatment, the total effective rate[98.36%(60/61)], visual acuity[(0.55±0.13)D] and visual field average light sensitivity(20.10±3.82) of the observation group were higher than those of the control group[86.89%(53/61),(0.41±0.11)D,(17.23±3.87)], the differences were significant(P<0.05). The difference of visual field loss(14.85±2.81) and visual field average damage[(5.19±1.41)dB] of the observation group were lower than those of the control group[(20.02±2.97),(8.05±1.89)dB], the differences were significant(P<0.05). The adverse reaction rate of the observation group was slightly higher than that of the control group, but the difference was not significant(P>0.05). Conclusions Breviscapine combined with nerve growth factor in the treatment of patients with ischemic optic neuropathy can significantly enhance the visual acuity level, improve visual field defect, and improve the clinical efficacy. Although Breviscapine increases the incidence of adverse reactions to some extent, it is within the tolerance range of patients.